肾移植受者中已患糖尿病的GLP-1受体激动剂应用:一项回顾性队列研究
使用与死亡删失移植物丢失风险降低49%(aSHR 0.51)及死亡率降低31%(aHR 0.69)相关,但糖尿病视网膜病变风险升高(aHR 1.49)。作者认为需临床试验确认。
要点
- 肾移植后使用GLP-1受体激动剂与死亡删失移植物丢失风险降低49%相关(aSHR 0.51)。
- 使用GLP-1受体激动剂与全因死亡率降低31%相关(aHR 0.69)。
- 安全性终点罕见,但糖尿病视网膜病变风险升高(aHR 1.49)。
核心结论
- GLP-1受体激动剂与更好的移植物和患者生存相关,作者认为需要临床试验来确认这些发现。
研究设计与样本
- 美国基于全国登记系统与Medicare理赔数据链接的回顾性队列研究,纳入移植时患2型糖尿病且以Medicare为主要保险的肾移植受者。
- 采用Fine-Gray子分布风险模型估计死亡删失移植物丢失,扩展Cox模型用于死亡率和安全性终点,模型纳入逆概率治疗加权。
- 另构建按移植后生存时间匹配的队列,每个GLP-1受体激动剂使用者匹配一名未起始GLP-1受体激动剂且带功能移植物存活的受者。
主要发现
- GLP-1受体激动剂使用者较未使用者更年轻(移植时中位年龄57岁[IQR 49-64] vs 60岁[51-66],p<0.0001),女性比例更高(786例[39.9%] vs 5645例[35.2%],p<0.0001)。
- 在按生存时间匹配的队列中,5年未调整死亡删失移植物丢失累积发生率GLP-1受体激动剂使用者为6.0%,未使用者为10.7%(Gray检验p=0.004)。
- 在按生存时间匹配的队列中,5年未调整死亡率累积发生率GLP-1受体激动剂使用者为17.0%,未使用者为25.8%(log-rank p=0.0006)。
- 5年未调整死亡率累积发生率GLP-1受体激动剂使用者为13.5%,未使用者为19.9%(log-rank p<0.0001)。
- GLP-1受体激动剂使用与死亡删失移植物丢失发生率降低49%相关(aSHR 0.51,95%CI 0.36-0.71;p=0.0001),与死亡率降低31%相关(aHR 0.69,95%CI 0.55-0.86;p=0.001)。
关键数值与推荐
- 按生存时间匹配后,死亡删失移植物丢失aSHR 0.53(95%CI 0.37-0.75;p=0.0005),死亡率aHR 0.70(95%CI 0.55-0.88;p=0.003)。
- 安全性终点罕见且与GLP-1受体激动剂无关,但糖尿病视网膜病变除外(aHR 1.49,95%CI 1.11-2.00;p=0.008)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipients. However, kidney transplant recipients are distinct from GLP-1 receptor agonist trial participants, with longer diabetes duration and severity, greater end-organ damage, increased cardiovascular risk, and multimorbidity. We examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes. METHODS: This USA-based retrospective cohort study included kidney transplant recipients with type 2 diabetes at transplantation and Medicare as their primary insurance from a national registry linked with Medicare claims. Post-transplantation GLP-1 receptor agonist use was identified through Medicare claims. Death-censored graft loss was estimated using the Fine-Gray sub-distribution hazard model and extended Cox models were used for mortality and safety endpoints. Models incorporated inverse probability of treatment weights. To further test whether bias could affect the main results, a cohort was created in which each GLP-1 receptor agonist user was matched with a kidney transplant recipient who had not started a GLP-1 receptor agonist, was alive with a functioning graft, and had accrued the same amount of post-transplant survival time. FINDINGS: Between Jan 1, 2013 and Dec 31, 2020, we identified 44 536 first time kidney transplant recipients with Medicare as primary payer in the 6 months before and at transplantation. 24 192 patients were excluded as they did not have type 2 diabetes. 2328 patients were ineligible (1916 had missing values and 412 used GLP-1 receptor agonists before transplantation). The primary cohort thus consisted of 18 016 kidney transplant recipients with diabetes. Of these patients, 1969 (10·9%) had at least one GLP-1 receptor agonist prescription filled post-transplant. Compared with patients who had not received a GLP-1 receptor agonist, GLP-1 receptor agonist users were younger (median age at transplant 57 years [IQR 49-64] vs 60 years [51-66], p<0·0001) and more likely to be female (786 [39·9%] vs 5645 [35·2%], p<0·0001). Among GLP-1 receptor agonist users, 552 [28·0%] were non-Hispanic White, 703 [35·7%] were non-Hispanic Black, and 568 [28·8%] were Hispanic. The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 receptor agonist initiation was 6·0% for GLP-1 receptor agonist users and 10·7% for non-users (Gray's test p=0·004). The 5-year unadjusted cumulative incidence for mortality from a cohort matched on survival time before GLP-1 receptor agonist initiation was 17·0% for GLP-1 receptor agonist users and 25·8% for non-users (log-rank p=0·0006). The 5-year unadjusted cumulative incidence for mortality was 13·5% for GLP-1 receptor agonist users and 19·9% for non-users (log-rank p<0·0001). GLP-1 receptor agonist use was associated with a 49% lower incidence of death-censored graft loss (adjusted subhazard ratio [aSHR] 0·51, 95% CI 0·36-0·71; p=0·0001) and 31% lower mortality (adjusted hazard ratio [aHR] 0·69, 95% CI 0·55-0·86; p=0·001). Inferences were robust when matched on survival time (death-censored graft loss aSHR 0·53, 95% CI 0·37-0·75; p=0·0005; mortality aHR 0·70, 95% CI 0·55-0·88; p=0·003). Safety endpoints were rare and not associated with GLP-1 receptor agonists, with the exception of diabetic retinopathy (aHR 1·49, 1·11-2·00; p=0·008). INTERPRETATION: GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings. FUNDING: National Institutes of Health.
引用
- Orandi BJ, Chen Y, Li Y, et al. GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol. 2025. PMID: 40056927. doi:10.1016/S2213-8587(24)00371-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。